Trump Wins… But Elon Says Get Ready to Brace

Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back…

Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov

ACRS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 6.40%

Insider Buying (Last 12 Months): $4,476,644.42

Insider Selling (Last 12 Months): $0.00

Aclaris Therapeutics Insider Trading History Chart

Aclaris Therapeutics Share Price & Price History

^$3.80

▼ -0.52 (-12.04%)

As of 11/22/2024 01:00 AM ET

Days: 30 | 90 | 365

JD Vance Predicts: Wall Street vs. Trump & Your Money

From Priority Gold | Ad

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Aclaris Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Anand Mehra	Director	Buy	666,666	$2.25	$1,499,998.50	710,030
7/30/2024	Braden Michael Leonard	Major Shareholder	Buy	173,730	$1.30	$225,849.00	13,776,421
7/22/2024	Braden Michael Leonard	Major Shareholder	Buy	17,716	$1.33	$23,562.28	13,602,691
7/18/2024	Braden Michael Leonard	Major Shareholder	Buy	130,317	$1.30	$169,412.10	13,578,286
7/5/2024	Braden Michael Leonard	Major Shareholder	Buy	123,017	$1.15	$141,469.55	13,447,969
7/3/2024	Braden Michael Leonard	Major Shareholder	Buy	143,288	$1.16	$166,214.08	13,324,952
7/1/2024	Braden Michael Leonard	Major Shareholder	Buy	107,434	$1.14	$122,474.76	13,095,572
6/27/2024	Braden Michael Leonard	Major Shareholder	Buy	235,000	$1.15	$270,250.00	11,787,134
6/17/2024	Braden Michael Leonard	Major Shareholder	Buy	150,000	$1.13	$169,500.00	11,502,134
6/13/2024	Braden Michael Leonard	Major Shareholder	Buy	528,621	$1.15	$607,914.15	11,007,134
6/11/2024	Braden Michael Leonard	Major Shareholder	Buy	1,000,000	$1.08	$1,080,000.00	10,395,934
10/23/2023	Joseph Monahan	Insider	Sell	6,000	$5.08	$30,480.00	129,724
8/28/2023	James Loerop	Insider	Buy	14,705	$6.80	$99,994.00	21,688
8/21/2023	Joseph Monahan	Insider	Sell	6,000	$7.32	$43,920.00	135,724
6/20/2023	Joseph Monahan	Insider	Sell	6,000	$10.28	$61,680.00	141,724
3/9/2023	Douglas J Manion	CEO	Buy	6,500	$7.74	$50,310.00	6,500
3/2/2023	Joseph Monahan	Insider	Sell	14,800	$12.37	$183,076.00	151,261
3/2/2023	Kevin Balthaser	CFO	Sell	1,000	$12.29	$12,290.00	4,650
3/2/2023	Neal Walker	Director	Sell	29,000	$12.37	$358,730.00	1,285,188
2/8/2023	James Loerop	Insider	Sell	4,267	$13.89	$59,268.63	6,983
1/3/2023	Neal Walker	Director	Sell	25,000	$15.25	$381,250.00	1,220,763
12/15/2022	Joseph Monahan	Insider	Sell	5,000	$15.88	$79,400.00	96,386
10/26/2022	Andrew N Schiff	Director	Sell	14,540	$17.00	$247,180.00	488,381
10/24/2022	Andrew N Schiff	Director	Sell	14,616	$17.01	$248,618.16	514,939
10/17/2022	Andrew N Schiff	Director	Sell	19,944	$16.05	$320,101.20	561,648
10/17/2022	Joseph Monahan	Insider	Sell	5,000	$15.98	$79,900.00	101,386
10/6/2022	Andrew N Schiff	Director	Sell	37,839	$16.54	$625,857.06	588,916
10/4/2022	Andrew N Schiff	Director	Sell	7,700	$16.01	$123,277.00	626,755
6/17/2022	Andrew N. Schiff	Director	Sell	19,565	$15.14	$296,214.10
4/25/2022	Neal Walker	CEO	Sell	20,000	$15.18	$303,600.00	1,245,763
4/21/2022	Neal Walker	CEO	Sell	25,000	$15.24	$381,000.00	1,290,763
4/18/2022	Joseph Monahan	Insider	Sell	30,000	$16.28	$488,400.00	106,386
3/11/2022	Neal Walker	CEO	Sell	56,303	$15.91	$895,780.73
3/10/2022	Frank Ruffo	CFO	Sell	12,823	$15.55	$199,397.65
3/10/2022	Joseph Monahan	Insider	Sell	27,165	$15.71	$426,762.15
2/9/2022	Joseph Monahan	Insider	Sell	383	$12.68	$4,856.44

[625,000% Gain] – Are You Ready for the Next Altcoin Boom?

From Crypto Swap Profits | Ad

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

SEC Filings (Institutional Ownership Changes) for Aclaris Therapeutics (NASDAQ:ACRS)

98.34% of Aclaris Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Aclaris Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/16/2024	Geode Capital Management LLC	846,446	$0.97M	0.0%	+9.3%	1.185%
11/15/2024	Jane Street Group LLC	82,727	$95K	0.0%	-75.3%	0.116%
11/15/2024	State Street Corp	188,721	$0.22M	0.0%	-4.0%	0.264%
11/15/2024	Jacobs Levy Equity Management Inc.	915,509	$1.05M	0.0%	N/A	1.282%
11/15/2024	HighTower Advisors LLC	305,814	$0.35M	0.0%	-2.2%	0.428%
11/15/2024	Point72 Asia Singapore Pte. Ltd.	52,052	$60K	0.0%	-51.8%	0.073%
11/14/2024	Stonepine Capital Management LLC	2,458,873	$2.83M	1.8%	+27.6%	3.442%
11/13/2024	FMR LLC	545,972	$0.63M	0.0%	-20.8%	0.764%
11/8/2024	Connor Clark & Lunn Investment Management Ltd.	332,406	$0.38M	0.0%	+187.6%	0.466%
11/5/2024	BML Capital Management LLC	14,250,000	$16.39M	9.6%	+9.7%	19.973%
11/5/2024	GSA Capital Partners LLP	255,032	$0.29M	0.0%	-24.3%	0.357%
10/23/2024	Assenagon Asset Management S.A.	185,777	$0.21M	0.0%	N/A	0.261%
10/8/2024	Trium Capital LLP	1,912,990	$2.20M	0.6%	+1.1%	2.684%
9/16/2024	Point72 Asia Singapore Pte. Ltd.	107,929	$0.12M	0.0%	N/A	0.151%
8/21/2024	Stonepine Capital Management LLC	1,927,446	$2.12M	1.9%	N/A	2.705%
8/15/2024	Millennium Management LLC	3,336,850	$3.67M	0.0%	+1.9%	4.682%
8/15/2024	AQR Capital Management LLC	386,177	$0.43M	0.0%	-36.9%	0.542%
8/15/2024	Point72 Asia Singapore Pte. Ltd.	107,929	$0.12M	0.0%	N/A	0.151%
8/12/2024	XTX Topco Ltd	24,452	$27K	0.0%	-80.1%	0.034%
8/9/2024	Renaissance Technologies LLC	922,200	$1.01M	0.0%	-44.9%	1.294%
8/9/2024	Dimensional Fund Advisors LP	76,759	$84K	0.0%	-13.8%	0.108%
8/6/2024	Trium Capital LLP	1,892,050	$2.08M	0.3%	N/A	2.655%
8/6/2024	Acadian Asset Management LLC	1,913,449	$2.10M	0.0%	-10.4%	2.685%
8/1/2024	Rhumbline Advisers	42,005	$46K	0.0%	-56.8%	0.059%
7/30/2024	Deuterium Capital Management LLC	72,091	$79K	0.1%	-9.9%	0.101%
5/16/2024	Bain Capital Life Sciences Investors LLC	3,000,000	$3.72M	0.3%	-14.3%	4.210%
5/10/2024	Acadian Asset Management LLC	2,135,367	$2.65M	0.0%	-9.2%	2.996%
5/10/2024	Vanguard Group Inc.	4,929,775	$6.11M	0.0%	+4.4%	6.918%
5/8/2024	Russell Investments Group Ltd.	62,772	$78K	0.0%	+5,265.1%	0.088%
5/7/2024	SG Americas Securities LLC	32,843	$41K	0.0%	+69.5%	0.046%
5/7/2024	Marquette Asset Management LLC	83,979	$0.10M	0.0%	N/A	0.118%
5/7/2024	Deuterium Capital Management LLC	79,993	$99K	0.2%	N/A	0.112%
5/3/2024	GSA Capital Partners LLP	679,137	$0.84M	0.1%	-57.2%	0.953%
5/1/2024	BNP Paribas Financial Markets	241,101	$0.30M	0.0%	+10.9%	0.338%
5/1/2024	Mirae Asset Global Investments Co. Ltd.	31,552	$39K	0.0%	N/A	0.044%
4/23/2024	BML Capital Management LLC	9,395,934	$11.65M	7.7%	+1,338.7%	13.248%
2/15/2024	Octagon Capital Advisors LP	100,000	$0.11M	0.0%	N/A	0.141%
2/13/2024	Bain Capital Life Sciences Investors LLC	3,500,000	$3.68M	0.4%	+2.9%	4.944%
2/7/2024	Monaco Asset Management SAM	979,399	$1.03M	0.3%	N/A	1.384%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	43,784	$46K	0.0%	+115.5%	0.062%
1/30/2024	BML Capital Management LLC	653,107	$0.69M	0.5%	N/A	0.923%
1/30/2024	Strs Ohio	193,000	$0.20M	0.0%	+256.7%	0.273%
1/30/2024	Vontobel Holding Ltd.	30,268	$32K	0.0%	+128.8%	0.043%
12/18/2023	Vanguard Group Inc.	3,363,046	$23.04M	0.0%	+1.0%	4.751%
12/6/2023	Citigroup Inc.	11,864	$81K	0.0%	-60.6%	0.017%
12/1/2023	Wellington Management Group LLP	6,979,844	$47.81M	0.0%	-8.6%	9.860%
11/14/2023	Blackstone Inc.	1,261,425	$8.64M	0.0%	+9,578.7%	1.782%
11/14/2023	Schonfeld Strategic Advisors LLC	269,746	$1.85M	0.0%	-40.6%	0.381%
11/14/2023	Corton Capital Inc.	14,916	$0.10M	0.1%	N/A	0.021%
11/14/2023	Trexquant Investment LP	127,851	$0.88M	0.0%	N/A	0.181%
11/13/2023	Algert Global LLC	45,120	$0.31M	0.0%	N/A	0.064%
11/13/2023	FMR LLC	661,300	$4.53M	0.0%	-11.6%	0.934%
11/13/2023	Lord Abbett & CO. LLC	453,954	$3.11M	0.0%	+14.0%	0.641%
11/9/2023	Deutsche Bank AG	154,309	$1.06M	0.0%	-85.8%	0.218%
11/8/2023	HighTower Advisors LLC	369,802	$2.53M	0.0%	-2.6%	0.522%
11/7/2023	Barclays PLC	234,150	$1.60M	0.0%	+174.2%	0.331%
11/6/2023	Assenagon Asset Management S.A.	687,135	$4.71M	0.0%	+7.9%	0.971%
10/25/2023	Zurcher Kantonalbank Zurich Cantonalbank	20,317	$0.14M	0.0%	+42.6%	0.029%
10/13/2023	SG Americas Securities LLC	151,704	$1.04M	0.0%	+20.1%	0.214%
9/21/2023	Barclays PLC	85,389	$0.89M	0.0%	-54.7%	0.121%
8/15/2023	HighVista Strategies LLC	86,103	$0.89M	0.4%	-56.5%	0.122%
8/15/2023	Braidwell LP	2,901,194	$30.09M	1.0%	-11.3%	4.098%
8/11/2023	Westwood Holdings Group Inc.	51,023	$0.53M	0.0%	N/A	0.072%
8/11/2023	Hsbc Holdings PLC	249,842	$2.61M	0.0%	N/A	0.353%
8/7/2023	Principal Financial Group Inc.	19,133	$0.20M	0.0%	+13.0%	0.027%
8/4/2023	American International Group Inc.	33,429	$0.35M	0.0%	+7.2%	0.047%
8/3/2023	Los Angeles Capital Management LLC	75,006	$0.78M	0.0%	N/A	0.106%
8/3/2023	Barclays PLC	85,389	$0.89M	0.0%	-54.7%	0.121%
8/3/2023	Bank of New York Mellon Corp	242,426	$2.51M	0.0%	+5.3%	0.343%
7/31/2023	Strs Ohio	54,100	$0.56M	0.0%	+8.4%	0.077%
7/25/2023	Assenagon Asset Management S.A.	636,829	$6.60M	0.0%	+49.6%	0.901%
7/10/2023	SG Americas Securities LLC	126,347	$1.31M	0.0%	+323.4%	0.179%
5/16/2023	BVF Inc. IL	3,360,941	$27.19M	1.0%	+2.6%	4.755%
5/16/2023	Bain Capital Life Sciences Investors LLC	3,400,000	$27.51M	3.4%	N/A	4.810%
5/15/2023	Commodore Capital LP	635,000	$5.14M	0.8%	-66.2%	0.898%
5/15/2023	Ghost Tree Capital LLC	425,000	$3.44M	1.0%	N/A	0.601%
5/12/2023	Wellington Management Group LLP	7,372,601	$59.64M	0.0%	+34.4%	10.431%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	176,650	$1.43M	0.0%	+948.6%	0.250%
5/10/2023	Ovata Capital Management Ltd	15,000	$0.12M	0.1%	N/A	0.021%
5/2/2023	Amalgamated Bank	9,098	$74K	0.0%	-13.0%	0.013%
4/28/2023	SG Americas Securities LLC	29,843	$0.24M	0.0%	+305.4%	0.042%
4/27/2023	Strs Ohio	49,900	$0.40M	0.0%	+37.1%	0.071%
4/18/2023	Assenagon Asset Management S.A.	425,828	$3.45M	0.0%	+118.5%	0.639%
4/12/2023	Vontobel Holding Ltd.	14,228	$0.12M	0.0%	N/A	0.021%
3/23/2023	MetLife Investment Management LLC	33,899	$0.53M	0.0%	+8.4%	0.051%
2/22/2023	Teachers Retirement System of The State of Kentucky	57,009	$0.90M	0.0%	+5.6%	0.085%
2/15/2023	Braidwell LP	2,393,985	$37.71M	1.3%	N/A	3.590%
2/14/2023	Verition Fund Management LLC	405,568	$6.39M	0.1%	+8.9%	0.608%
2/13/2023	Renaissance Technologies LLC	1,121,752	$17.67M	0.0%	-5.4%	1.682%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	16,846	$0.27M	0.0%	-37.3%	0.025%
2/10/2023	HRT Financial LP	45,535	$0.72M	0.0%	N/A	0.068%
2/10/2023	Cheyne Capital Management UK LLP	50,964	$0.80M	1.4%	N/A	0.076%
2/9/2023	Mirae Asset Global Investments Co. Ltd.	31,135	$0.49M	0.0%	+16.6%	0.047%
2/9/2023	Aisling Capital Management LP	434,455	$6.84M	4.5%	-31.5%	0.652%
2/9/2023	Principal Financial Group Inc.	18,208	$0.29M	0.0%	+11.0%	0.027%
2/9/2023	HighTower Advisors LLC	192,424	$3.03M	0.0%	+229.8%	0.289%
2/8/2023	Swiss National Bank	112,600	$1.77M	0.0%	+1.9%	0.169%
2/7/2023	Fox Run Management L.L.C.	16,350	$0.26M	0.1%	+9.5%	0.025%
2/7/2023	Handelsbanken Fonder AB	14,800	$0.23M	0.0%	N/A	0.022%
2/3/2023	Frazier Life Sciences Management L.P.	290,189	$4.57M	0.3%	-28.9%	0.435%

Data available starting January 2016

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Today's Range

Now: $3.80

$3.80

$4.44

50 Day Range

MA: $1.77

$1.12

$4.59

52 Week Range

Now: $3.80

$0.77

$5.17

Volume

2,974,979 shs

Average Volume

1,414,714 shs

Market Capitalization

$271.44 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.1

Who are the company insiders with the largest holdings of Aclaris Therapeutics?: Aclaris Therapeutics' top insider shareholders include:
Braden Michael Leonard (Major Shareholder)
Neal Walker (Director)
Anand Mehra (Director)
Joseph Monahan (Insider)
James Loerop (Insider)
Douglas J Manion (CEO)
Kevin Balthaser (CFO)
Learn More about top insider investors at Aclaris Therapeutics.
Who are the major institutional investors of Aclaris Therapeutics?: Aclaris Therapeutics' top institutional investors include:
BML Capital Management LLC — 19.97%
Stonepine Capital Management LLC — 3.44%
Trium Capital LLP — 2.68%
Jacobs Levy Equity Management Inc. — 1.28%
Geode Capital Management LLC — 1.19%
FMR LLC — 0.76%
Learn More about top institutional investors of Aclaris Therapeutics stock.
Which major investors are selling Aclaris Therapeutics stock?: Within the last quarter, ACRS stock was sold by these institutional investors:
Jane Street Group LLC
FMR LLC
GSA Capital Partners LLP
Point72 Asia Singapore Pte. Ltd.
State Street Corp
HighTower Advisors LLC
Which major investors are buying Aclaris Therapeutics stock?: During the previous quarter, ACRS stock was purchased by institutional investors including:
BML Capital Management LLC
Jacobs Levy Equity Management Inc.
Stonepine Capital Management LLC
Connor Clark & Lunn Investment Management Ltd.
Assenagon Asset Management S.A.
Geode Capital Management LLC
Trium Capital LLP
During the previous year, these company insiders have bought Aclaris Therapeutics stock:
Braden Michael Leonard (Major Shareholder)
Neal Walker (Director)
Anand Mehra (Director)
Joseph Monahan (Insider)
Learn More investors buying Aclaris Therapeutics stock.